April 30, 2024

Study to Investigate the Efficacy and Safety of Retatrutide Once Weekly Compared with Semaglutide Once Weekly in Adult Participants with Type 2 Diabetes

A Phase 3, Randomized, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Retatrutide Once Weekly Compared with Semaglutide Once Weekly in Adult Participants with Type 2 Diabetes and Inadequate Glycemic Control with Metformin with or without SGLT2 Inhibitor (TRANSCEND-T2D-2)

TRANSCEND-T2D-2 is a clinical research study for people with type 2 diabetes.
This study will test if an investigational medicine (the medicine being studied) can
help with blood glucose (sugar) and weight management compared with an existing
treatment for type 2 diabetes.

  • Are aged 18 years or older
  • Have type 2 diabetes
  • Have been taking 1500mg or more of metformin each day for at least 3 months (with or without SGLT2i)
  • Have a BMI of 25 or more
  • Have HbA1c levels of 7.0% to 10.5%

To see if you qualify please contact at 205-996-4015, 205-934-5564 or via mail at tthoma@uab.edu or ccnrn@uab.edu